The basic biology and immunobiology of renal cell carcinoma: Considerations for the clinician

Urologic Clinics of North America

Volumn 30, Issue 3, 2003, Pages 423-436

  Uzzo, Robert G ^a   Cairns, Paul ^a   Al Saleem, Tahseen ^a   Hudes, Gary ^a   Haas, Naomi ^a   Greenberg, Richard E ^a   Kolenko, Vladimir ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIODIVERSITY; CLINICAL MEDICINE; EPIGENETICS; GENETIC ANALYSIS; HUMAN; IMMUNOBIOLOGY; KIDNEY CARCINOMA; LABORATORY DIAGNOSIS; MEDICAL RESEARCH; MICROENVIRONMENT; OUTCOMES RESEARCH; PATIENT COUNSELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TAXONOMY;

EID: 0041819704     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(03)00021-1     Document Type: Review

References (97)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-31.
3. Pantuck AJ, Zisman A, Rauch MK, et al. Incidental renal tumors. Urology 2000;56:190-6.
4. Yip SK, Cheng WS. Incidental renal cell carcinoma. Urology 2001;57:206-7.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.
6. Kavanagh DY, Carbone DP. Immunologic dysfunction in cancer. Hematol Oncol Clin North Am 1996;10:927-51.
7. Uzzo RG, Rayman P, Novick A, et al. Immune dysfunction in malignancy. AUA Update Series 2002;28:218-24.
8. Enquist E, Zambrano N, Zbar B, et al. Molecular genetics of renal cell carcinoma. In: Bukowski RM, Novick AC, editors. Renal cell carcinoma: molecular biology, immunology, and clinical management. Totowa (NJ): Humana Press; 2000. p. 79-93.
9. Knudson AG Jr. Genetics of human cancer. Annu Rev Genet 1986;20:231-51.
10. Uzzo RG, Novick AC. von Hippel-Lindau syndrome: clinical and molecular considerations for the urologist. AUA Update Series 1999;18:137-44.
11. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999;155:517-26.
12. Hatano N, Nishikawa NS, McElgunn C, et al. A comprehensive analysis of loss of heterozygosity caused by hemizygous deletions in renal cell carcinoma using a subtraction library. Mol Carcinog 2001;31:161-70.
13. Baylin SB, Herman JG, Graff JR, et al. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
14. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332:268-9.
15. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260:1317-20.
16. Gnarra JR, Lerman MI, Zbar B, et al. Genetics of renal cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995;22:3-8.
17. Maher ER. Kaelin WG. von Hippel-Lindau disease. Medicine (Baltimore) 1997;76:381-91.
18. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA 1995;273:564-70.
19. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3:2169-73.
20. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91:9700-4.
21. Stolle C, Glenn G, Zbar B, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1998;12:417-23.
22. Chen F, Kishida T, Yao M, et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
23. Zbar B. Von Hippel-Lindau disease and sporadic renal cell carcinoma. Cancer Surv 1995;25:219-32.
24. van den Berg E, Dijkhuizen T, Oosterhuis JW, et al. Cytogenetic classification of renal cell cancer. Cancer Genet Cytogenet 1997;95:103-7.
25. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
26. Brown JA, Takahashi S, Alcaraz A, et al. Fluorescence in situ hybridization analysis of renal oncocytoma reveals frequent loss of chromosome Y and 1. J Urol 1996;156:31-5.
27. Dobin SM, Harris CP, Reynolds JA, et al. Cytogenetic abnormalities in renal oncocytic neoplasms. Genes Chromosomes Cancer 1992;4:25-31.
28. Kovacs G, Welter C, Wilkens L, et al. Renal oncocytoma: a phenotypic and genotypic entity of renal parenchymal tumors. Am J Pathol 1989;134:967-71.
29. Polascik TJ, Cairns P, Epstein JI, et al. Distal nephron renal tumors: microsatellite allelotype. Cancer Res 1996;56:1892-5.
30. Kovacs A, Storkel S, Thoenes W, et al. Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J Pathol 1992;167:273-7.
31. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol 1994;145:356-64.
32. van den Berg E, van der Hout AH, Oosterhuis JW, et al. Cytogenetic analysis of epithelial renal cell tumors: relationship with a new histopathological classification. Int J Cancer 1993;55:223-7.
33. Kenck C, Wilhelm M, Bugert P, et al. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996;179:157-61.
34. Martinez Barba E, Lopez Cubillana P, Sola Perez J, et al. Bellini duct carcinoma of the kidney. Br J Urol 1997;80:342-4.
35. Fuzesi L, Cober M, Mittermayer C. Collecting duct carcinoma: cytogenetic characterization. Histopathology 1992;21:155-60.
36. Steiner G, Cairns P, Polascik TJ, et al. High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32.1-32.2. Cancer Res 1996;56:5044-6.
37. Iliopoulos O, Eng C. Genetic and clinical aspects of familial renal neoplasms. Semin Oncol 2000;27:138-49.
38. Kibel A, Iliopoulos O, DeCaprio JA, et al. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995;269:1444-6.
39. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000;27:390-401.
40. Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo 1998;12:571-8.
41. Bukowski RM. Immunotherapy in renal cell carcinoma. Oncology (Huntingt) 1999;13:801-810; discussion, 810-3.
42. Wang Q, Redovan C, Tubbs R, et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 1995;61:780-5.
43. Kowalczyk D, Skorupski W, Kwias Z, et al. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 1997;80:543-7.
44. Angevin E, Kremer F, Gaudin C, et al. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity. Int J Cancer 1997;72:431-40.
45. Maeurer MJ, Martin DM, Castelli C, et al. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1995;41:111-21.
46. Finke JH, Rayman P, Hart L, et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation. J Immunother Emphasis Tumor Immunol 1994;15:91-104.
47. Finke JH, Kierstead LS, Ranieri E, et al. Immunologic response to renal cell carcinoma. In: Bukowski RM, Novick AC, editors. Renal cell carcinoma: molecular biology, immunology and clinical management. Totowa (NJ): Humana Press; 2000. p. 39-62.
48. Altman A, Coggeshall K, Mustelin T. Molecular events mediating T cell activation. Adv Immunol 1990;48:227-360.
49. Ullman KS, Northrop JP, Verweij CJ, et al. Transmission of signals from the T cell lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol 1990;8:421-52.
50. Neumann E, Engelsberg A, Decker J, et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 1998;58:4090-5.
51. Robbins PF, Kawakami K. Human tumor antigens recognized by T cells. Curr Opin Immunol 1997;8:628-36.
52. Kessler JH, Beekman NJ, Bres-Vloemans SA, et al. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J Exp Med 2001;193:73-88.
53. Kawagoe N, Shintaku I, Yutani S, et al. Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 2000;164:2090-5.
54. Shintaku I, Kawagoe N, Yutani S, et al. Expression of the SART1 tumor rejection antigen in renal cell carcinoma. Urol Res 2000;28:178-84.
55. Mulders P, Tso CL, Gitlitz B, et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999;5:445-54.
56. Schendel DJ, Oberneder R, Falk CS, et al. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 1997;75:400-13.
57. Nakagomi H, Pisa P, Pisa EK, et al. Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 1995;63:366-71.
58. Alexander JP, Kudoh S, Melsop KA, et al. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993;53:1380-7.
59. Uzzo RG, Rayman P, Novick AC, et al. Molecular mechanisms of immune dysfunction in renal cell carcinoma. In: Bukowski RM, Novick AC, editors. Renal cell carcinoma: molecular biology, immunology and clinical management. Totowa (NJ): Humana Press; 2000. p. 63-78.
60. Tartour E, Latour S, Mathiot C, et al. Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 1995;63:205-12.
61. Kudoh S, Stanley J, Edinger MG, et al. T lymphocytes infiltrating renal cell carcinoma have a reduced expression of transferrin receptor. Int J Cancer 1994;58:369-75.
62. Kudoh S, Redovan C, Rayman P, et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother 1997;20:479-87.
63. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999;91:332.
64. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997;278:1054.
65. Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999;59:71.
66. Silva JM, Dominguez G, Garcia JM, et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999;59:3251.
67. Eisenberger CF, Schoenberg M, Enger C, et al. Diagnosis of renal cancer by molecular urinalysis. J Natl Cancer Inst 1999;91:2028-32.
68. Goessl C, Heicappell R, Munker R, et al. Microsatellite analysis of plasma DNA from patients with renal cell carcinoma. Cancer Res 1998;58:4728-32.
69. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
70. Esteller M, Tortola S, Toyota M, et al. Hypermethylation associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutation status. Cancer Res 2000;60:129-33.
71. Dammann R, Li C, Yoon JH. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
72. Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSFIA, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001;98:7504-9.
73. Esteller M, Corn PG, Urena JM, et al. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 1998;58:4515-8.
74. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene 06-methyl-guanine DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K ras in colorectal tumorigenesis. Cancer Res 2000;60:2368-71.
75. Battagli C, Krassenstein R, Al-Saleem T, et al. Methylation specific PCR-based detection of renal cell carcinoma. Proc Am Assoc Cancer Res 2002;43:398.
76. Bostwick DG, Murphy GP. Diagnosis and prognosis of renal cell carcinoma: highlights from an international consensus workshop. Semin Urol Oncol 1998;16:46-52.
77. Nativ O, Sabo E, Reiss A, et al. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma. Urology 1998;51:693-6.
78. Yoshino S, Kato M, Okada K. Prognostic significance of microvessel count in low stage renal cell carcinoma. Int J Urol 1995;2:156-60.
79. Carducci MA, Piantadosi S, Pound CR, et al. Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 1999;53:44-9.
80. Cronin KJ, Williams NN, Kerin MJ, et al. Proliferating cell nuclear antigen: a new prognostic indicator in renal cell carcinoma. J Urol 1994;152:834-6.
81. Delahunt B, Bethwaite PB, Thornton A, et al. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling: correlation with clinical outcome. Cancer 1995;75:2714-9.
82. Papadopoulos I, Rudolph P, Weichert-Jacobsen K. Value of p53 expression, cellular proliferation, and DNA content as prognostic indicators in renal cell carcinoma. Eur Urol 1997;32:110-7.
83. Nakagawa Y, Tsumatani K, Kurumatani N, et al. Prognostic value of nm23 protein expression in renal cell carcinomas. Oncology 1998;55:370-6.
84. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-40.
85. Friedrich CA. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 2001;10:763-7.
86. Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol 2001;19:98-102.
87. Bukowski RM. Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001;19:148-54.
88. Chouaib S, Asselin-Paturel A, Mami-Chouaib F, et al. The host immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18:493-7.
89. Uzzo RG, Clark PE, Rayman P, et al. Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 1999;91:718-21.
90. Uzzo RG, Rayman P, Kolenko V, et al. Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest 1999;104:769-76.
91. Uzzo RG, Rayman P, Kolenko V, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5:1219-29.
92. Brown JA, Anderl KL, Borell TJ, et al. Simultaneous chromosome 7 and 17 gain and sex chromosome loss provide evidence that renal metanephric adenoma is related to papillary renal cell carcinoma. J Urol 1997;158:370-4.
93. Cairns P, Tokino K, Eby Y, et al. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res 1995;55:224-7.
94. Herbers J, Schullerus D, Muller H, et al. Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas. Genes Chromosomes Cancer 1997;19:29-35.
95. Schullerus D, Herbers J, Chudek J, et al. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of nonpapillary renal cell carcinomas. J Pathol 1997;183:151-5.
96. Schullerus D, von Knobloch R, Chudek J, et al. Microsatellite analysis reveals deletion of a large region at chromosome 8p in conventional renal cell carcinoma. Int J Cancer 1999;80:22-4.
97. van den Berg E, Dijkhuizen T. Classification of renal cell cancer based on (cyto)genetic analysis. Contrib Nephrol 1999;128:51-61.